It has helped in reducing the admission rates in hospitals and has improved the Medicare services. Contact Us:
Email:Sales@Eximine.Com
Phone:8929979895
visit:https://eximine.com/
Our company is a market research company which provide USA import export data, India Import export data and china Import export data etc.
Which will help you to manage and achieve of something definite,import-export data reports, authenticated analysis, and accurate forecasts.For more information Contact Us:Email:Sales@Eximine.ComPhone:9643566317visit:https://eximine.com/
ESMO Abstracts:CheckMate 067 Results at ESMO 2020Abstract No : Abstract: #1105PIndication : MelanomaIntervention : NivolumabCompany : Bristol-Myers SquibbTechnology : PD-1/PD-L1 inhibitorMixture models adequately captured the survival plateaus in CheckMate 067 and suggested a higher proportion of LTSs with NIVO and NIVO+IPI than with IPI.
These methods may be used in the indirect estimation of auxiliary outcomes, such as time to subsequent treatment and impact of subsequent treatments on LTSs.Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-067-NCT01844505-esmo-2020 CheckMate -577 Results at ESMO 2020Abstract No : Abstract: #LBA9Indication : Esophageal Cancer, Gastroesophageal junction cancerIntervention : NivolumabCompany : Bristol-Myers SquibbTechnology : PD-1/PD-L1 inhibitorAdjuvant nivolumab is the first therapeutic to provide a statistically significant and clinically meaningful improvement in DFS vs placebo and a well-tolerated safety profile in patients with resected EC/GEJC, who have received neoadjuvant CRT.
These results represent the first treatment advance in many years for these patients, potentially establishing adjuvant nivolumab as a new standard of care.Read More: https://www.delveinsight.com/esmo-conference-2020/article/checkmate-577-esmo-2020 KEYNOTE-590 Results at ESMO 2020Abstract No : Abstract #LBA8Indication : Esophageal cancerIntervention : PembrolizumabCompany : Merck & Co.Technology : PD-1/PD-L1 inhibitorPembro + chemo provided superior OS, PFS, and ORR vs chemo, with a manageable safety profile in pts with untreated, advanced esophageal and EGJ cancer.
These data demonstrate that 1L pembro + chemo is a new standard of care in this pt population.Read More: https://www.delveinsight.com/esmo-conference-2020/article/keynote-590-NCT03189719-esmo-2020 ASCO Abstracts:ASCO: Results of KEYNOTE-426Abstract No : 5001Abstract Type : Oral Abstract SessionIndication : Renal Cell CarcinomaIntervention : Pembrolizumab + axitinibCompany : Merck & Co.Technology : Immune Checkpoint Inhibitor (ICI)Pembro + axi continued to demonstrate superior and durable antitumor activity vs sunitinib in pts with first-line aRCC with a 27-mo median follow up; no new safety signals were observed.Read More: https://www.delveinsight.com/asco-conference/article/NCT02853331
